Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy drug could be first defense against advanced skin cancer

NCT ID NCT06981325

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug cemiplimab as a first-line treatment for people with advanced basal cell carcinoma who have not received prior therapy. The study will enroll 34 participants and measure how many patients see their tumors shrink or disappear after six months. Cemiplimab works by helping the immune system recognize and attack cancer cells, offering a potential alternative to current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cemiplimab (a cancer immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If it works, this could offer a new first-line treatment option for advanced basal cell carcinoma, potentially shrinking tumors and delaying progression without needing prior therapies.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs, and the drug may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA (BCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL CARCINOMA (BCC) FIRST LINE TREATMENT

Contacts and locations

Locations

  • Helios Klinikum Erfurt

    RECRUITING

    Erfurt, Germany

  • Helios Klinikum Oberhausen

    RECRUITING

    Oberhausen, Germany

  • Johannes Wesling Klinikum

    RECRUITING

    Minden, Germany

  • Nationales Centrum für Tumorerkrankungen (NCT)

    RECRUITING

    Heidelberg, Germany

  • Universitätsklinikum Erlangen

    RECRUITING

    Erlangen, Germany

  • Universitätsklinikum Leipzig

    RECRUITING

    Leipzig, Germany

  • Universitätsklinikum Tübingen

    RECRUITING

    Tübingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.